ReShape Lifesciences Files S-1/A Amendment
Ticker: HIND · Form: S-1/A · Filed: Feb 13, 2025 · CIK: 1427570
| Field | Detail |
|---|---|
| Company | Reshape Lifesciences Inc. (HIND) |
| Form Type | S-1/A |
| Filed Date | Feb 13, 2025 |
| Risk Level | medium |
| Pages | 15 |
| Reading Time | 18 min |
| Key Dollar Amounts | $0.001, $2.81, $0, $2.705, $1.15 million |
| Sentiment | neutral |
Sentiment: neutral
Topics: sec-filing, s-1/a, corporate-update
Related Tickers: RSLS
TL;DR
ReShape Lifesciences filed an S-1/A on 2/13/25. Formerly Obalon. Check for new stock offerings.
AI Summary
ReShape Lifesciences Inc. filed an S-1/A amendment on February 13, 2025, for its registration statement (No. 333-284362). The company, formerly known as Obalon Therapeutics Inc. until February 20, 2008, is incorporated in Delaware and operates in the Pharmaceutical Preparations sector. Its principal executive offices are located at 18 Technology Dr, Suite 110, Irvine, California, 92618, with a contact phone number of (949) 429-6680.
Why It Matters
This filing indicates ongoing regulatory activity for ReShape Lifesciences, potentially related to new securities offerings or significant corporate changes that could impact investors.
Risk Assessment
Risk Level: medium — S-1/A filings often precede significant corporate actions like stock offerings, which can dilute existing shareholders or signal financial needs.
Key Numbers
- 333-284362 — SEC Registration Number (Identifies the specific registration statement being amended.)
- 20250213 — Filing Date (Indicates the date the amendment was submitted to the SEC.)
Key Players & Entities
- ReShape Lifesciences Inc. (company) — Registrant
- Obalon Therapeutics Inc. (company) — Former company name
- February 13, 2025 (date) — Filing date
- 333-284362 (registration_number) — SEC registration number
- 18 Technology Dr, Suite 110, Irvine, California, 92618 (address) — Principal executive offices
- (949) 429-6680 (phone_number) — Business phone number
- Paul F. Hickey (person) — President and Chief Executive Officer
FAQ
What is the purpose of this S-1/A filing?
This is an amendment to a Form S-1 registration statement, indicating potential updates or changes to previously filed information, often related to a securities offering.
When was ReShape Lifesciences Inc. formerly known as Obalon Therapeutics Inc.?
The company changed its name from Obalon Therapeutics Inc. on February 20, 2008.
Where are ReShape Lifesciences Inc.'s principal executive offices located?
The principal executive offices are located at 18 Technology Dr, Suite 110, Irvine, California, 92618.
What is the SIC code for ReShape Lifesciences Inc.?
The Standard Industrial Classification (SIC) code is 2834, which corresponds to Pharmaceutical Preparations.
Who is the President and Chief Executive Officer of ReShape Lifesciences Inc.?
Paul F. Hickey is the President and Chief Executive Officer.
Filing Stats: 4,547 words · 18 min read · ~15 pages · Grade level 14.8 · Accepted 2025-02-13 06:21:44
Key Financial Figures
- $0.001 — ne share of our common stock, par value $0.001 per share (the "Common Stock"or "common
- $2.81 — at an assumed public offering price of $2.81 per Unit, based upon the closing price
- $0 — luding one share of Common Stock, minus $0.001, and the remaining exercise price o
- $2.705 — orted on the Nasdaq Capital Market, was $2.705 per share. There is no established trad
- $1.15 million — development has received approximately $1.15 million dollars of nondilutive NIH grant suppor
- $5,000,000 — tal maximum aggregate purchase price of $5,000,000 (the "Purchase Shares"), upon the terms
- $833,333.34 — aggregate original principal amount of $833,333.34 (the "Note"), and also issued to Ascent
- $45,000 — ings from 66% to 50%, and (d) require a $45,000 cash extension fee to be paid by the Co
Filing Documents
- tm253570-7_s1a.htm (S-1/A) — 6326KB
- tm253570d8_ex1-1.htm (EX-1.1) — 119KB
- tm253570d8_ex4-32.htm (EX-4.32) — 110KB
- tm253570d8_ex4-33.htm (EX-4.33) — 98KB
- tm253570d8_ex4-34.htm (EX-4.34) — 117KB
- tm253570d8_ex5-1.htm (EX-5.1) — 14KB
- tm253570d8_ex10-27.htm (EX-10.27) — 214KB
- tm253570d8_ex-filingfees.htm (EX-FILING FEES) — 30KB
- lg_reshapelifescitm-4clr.jpg (GRAPHIC) — 14KB
- fc_keygrowth-4clr.jpg (GRAPHIC) — 46KB
- fc_figure1-4clr.jpg (GRAPHIC) — 127KB
- tb_vyomesproduct2-4c.jpg (GRAPHIC) — 19KB
- bc_figure3-4clr.jpg (GRAPHIC) — 37KB
- ph_figure4-4clr.jpg (GRAPHIC) — 23KB
- ph_figuretlr4-4clr.jpg (GRAPHIC) — 22KB
- bc_figure5-4clr.jpg (GRAPHIC) — 63KB
- lc_figure6-4clr.jpg (GRAPHIC) — 39KB
- tb_figure7-4clr.jpg (GRAPHIC) — 50KB
- bc_figure8-4clr.jpg (GRAPHIC) — 70KB
- lc_figure9-4clr.jpg (GRAPHIC) — 68KB
- bc_figure10-4clr.jpg (GRAPHIC) — 28KB
- bc_figurefunction10-4clr.jpg (GRAPHIC) — 27KB
- bc_figureemotional10-4clr.jpg (GRAPHIC) — 30KB
- lc_figure11-4clr.jpg (GRAPHIC) — 27KB
- lc_figureuveitis11-4clr.jpg (GRAPHIC) — 30KB
- lc_figurelyphocytes11-4clr.jpg (GRAPHIC) — 17KB
- bc_figure12-4clr.jpg (GRAPHIC) — 33KB
- bc_figure14-4clr.jpg (GRAPHIC) — 47KB
- bc_figure15-4clr.jpg (GRAPHIC) — 43KB
- bc_figure16-4clr.jpg (GRAPHIC) — 97KB
- lc_figure13-4clr.jpg (GRAPHIC) — 30KB
- lc_figure17-4clr.jpg (GRAPHIC) — 44KB
- tm253570d8_ex5-1img001.jpg (GRAPHIC) — 11KB
- tm253570d8_ex5-1img002.jpg (GRAPHIC) — 27KB
- 0001104659-25-012392.txt ( ) — 8500KB
RISK FACTORS
RISK FACTORS 12 CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS 53 CAPITALIZATION 54
USE OF PROCEEDS
USE OF PROCEEDS 56 MARKET AND DIVIDEND INFORMATION FOR OUR COMMON STOCK 57
MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS
MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS 58
BUSINESS
BUSINESS 72 EXECUTIVE AND DIRECTOR COMPENSATION 93 MANAGEMENT 96
SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT
SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT 103 DESCRIPTION OF EQUITY FINANCING TRANSACTION 105 DESCRIPTION OF CONVERTIBLE NOTE TRANSACTION 107
DESCRIPTION OF CAPITAL STOCK
DESCRIPTION OF CAPITAL STOCK 108
DESCRIPTION OF SECURITIES WE ARE OFFERING
DESCRIPTION OF SECURITIES WE ARE OFFERING 113 MATERIAL U.S. FEDERAL TAX CONSIDERATIONS FOR HOLDERS OF COMMON STOCK 117 PLAN OF DISTRIBUTION 124 RESHAPE AND VYOME UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL STATEMENTS 130 VYOME INFORMATION 142 LEGAL MATTERS 241 EXPERTS 241 WHERE YOU CAN FIND MORE INFORMATION 241 DISCLOSURE OF COMMISSION POSITION ON INDEMNIFICATION FOR SECURITIES ACT LIABILITY 241 i TABLE OF CONTENTS ABOUT THIS PROSPECTUS This prospectus is part of a registration statement on Form S-1 for the offering by us of shares of common stock. You should not assume that the information contained in this prospectus is accurate on any date subsequent to the date set forth on the front cover of this prospectus, even though this prospectus is delivered or our securities registered under the registration statement of which this prospectus forms a part are sold or otherwise disposed of on a later date. It is important for you to read and consider all information contained in this prospectus in making your investment decision. You should also read and consider the information in the documents to which we have referred you under the captions " Where You Can Find Additional Information " in this prospectus. Neither we nor the placement agent have authorized anyone to provide any information or to make any representation other than those contained in this prospectus. You must not rely upon any information or representation not contained in this prospectus. If anyone provides you with different or inconsistent information, you should not rely on it. This prospectus does not constitute an offer to sell or the solicitation of an offer to buy any of our securities other than the securities covered hereby, nor does this prospectus constitute an offer to sell or the solicitation of an offer to buy any securities of our company in any jurisdiction to any person to whom it is unlawful to make such offer or solicitation in such j